JPM: BioNTech Hikes COVID-19 Vaccine Output to 2B Doses in 2021—And Plans a Bigger Label, Too

Source: FierceHealthcare

With its Pfizer-partnered COVID-19 vaccine authorized in the U.S., Europe, the U.K. and a slate of other countries, German mRNA specialist BioNTech is wasting no time scaling up its 2021 pandemic ambitions—namely, 2 billion shots by year-end, plus a slate of new approvals and a temperature-stable formulation, too, according to a FierceHealthcare report.

BioNTech set its sights on producing 2 billion doses of its pandemic vaccine, now dubbed Comirnaty, this year, up from a previous estimate of 1.3 billion, CEO Uğur Şahin said at the virtual J.P. Morgan Healthcare Conference.

Read the full article.

Related Content